What are the odds of dying from breast cancer?
Evidence quality 4.88/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 5/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, subgroup
1 in 59
1.7% lifetime chance
range 1 in 77 to 1 in 38
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Breast cancer is the single most-feared disease in several women’s health surveys. A 2005 Society for Women’s Health Research poll found 22% of women named it the disease they feared most, ahead of heart disease despite the latter killing roughly seven times as many women. Almost everyone has heard the "1 in 8" figure — but that figure is the lifetime probability of *diagnosis*, not death. Public intuition reliably conflates the two, which is why breast cancer lives in the "calibrated about diagnosis, wrong about mortality" bucket.
Rough estimate: Most adults quote 1 in 8 and implicitly read it as a death rate
Actual
~670,000 breast cancer deaths per year globally (women)
global women, all ages
Show derivation
WHO reports ~670,000 global breast cancer deaths per year against an adult female population of roughly 3-4 billion, which gives an annual per-woman hazard near 1.7 per 10,000. Age-weighted over ~60 years of remaining adult life (most breast cancer deaths occur between ages 50 and 74, so the hazard in the second half of adult life is several-fold higher than the flat average), the implied global lifetime breast-cancer mortality for women sits around 1.5-2.0%. The American Cancer Society’s direct SEER-based estimate for US women is 2.3% (~1 in 43) — higher than the global figure primarily because competing mortality in low- and middle-income countries removes many women from the denominator before they reach peak breast-cancer age, not because breast cancer is "safer" in LMICs; case fatality is in fact worse there due to later diagnosis. Headline figure 0.017 (≈ 1 in 59) for the global women baseline, with an uncertainty band reaching up to the US direct estimate of ~0.023. Men are excluded from this headline (see regional breakdown) because their risk is roughly 100× lower and folding both sexes into one number hides the relevant asymmetry. Scope is global-adult-lifetime.
Caveats: This entry is lifetime *mortality* from breast cancer, not incidence. The widely…
This entry is lifetime *mortality* from breast cancer, not incidence. The widely quoted "1 in 8" figure is the lifetime probability a US woman will be *diagnosed* with invasive breast cancer; the lifetime probability she will *die* of it is about 1 in 43 per ACS — roughly 5.5× smaller. The diagnosis/death gap is the single most consistent perception mistake visitors make on this site. Survival also depends heavily on stage at diagnosis: SEER’s 5-year relative survival is 100% for localized disease (~64% of cases), 87% for regional spread, and 33% for distant metastases, so the aggregate number smooths over a very uneven outcome distribution. Male breast cancer exists but is roughly 100× rarer and is excluded from the headline number — see the regional breakdown for the male-specific figure.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Global average, women | 1 in 59 |
~670K deaths/yr across ~3.5B adult women (WHO / IARC GLOBOCAN 2022) |
| US women | 1 in 43 |
ACS direct SEER-based estimate: ~1 in 43 lifetime death, alongside ~1 in 8 lifetime diagnosis |
| East Africa / LMIC women | 1 in 45 |
Lower age-standardized incidence than high-income countries but meaningfully higher case-fatality due to late-stage diagnosis; the two effects roughly cancel and the lifetime death figure is comparable to the US |
| Men (all regions) | 1 in 3,333 |
Male breast cancer is ~100× rarer; roughly 0.5-1% of all breast cancers occur in men |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Charred meat & cancer
How much does eating charred or well-done grilled meat actually raise your cancer risk?
Low-fiber CRC risk
What are the odds of getting colorectal cancer from not eating enough fiber?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The headline everyone knows is “1 in 8”, and the headline is correct — for diagnosis. The lifetime probability that a US woman will be diagnosed with invasive breast cancer is about 13%, or roughly one in eight. The lifetime probability that a US woman will die of breast cancer is about 1 in 43 (2.3%), per the American Cancer Society’s direct SEER-based estimate. The gap between those two numbers — a factor of roughly 5.5 — is the single most consistent perception mistake on this site. Globally, across ~3.5 billion adult women and ~670,000 breast-cancer deaths per year in WHO’s GLOBOCAN 2022 numbers, the lifetime-mortality figure for a generic woman alive today sits around 1.5-2.0%, or roughly 1 in 59.
The reason the gap exists is survivorship. SEER reports a 5-year relative survival of 91.7% across all female breast cancer in the US, and 100% for localized disease, which is about 64% of new diagnoses at the point of detection. Regional spread drops survival to 87%, and distant metastatic disease to 33% — the aggregate number hides a very uneven stage distribution, and “breast cancer” in a wealthy country with compliant screening is a very different prognostic entity than “breast cancer” diagnosed at stage IV. This is also why the regional story is subtle: age- standardized breast-cancer incidence is lower in much of sub-Saharan Africa and South Asia than in North America, but case fatality is meaningfully higher because diagnosis is later, and the two effects roughly cancel in the lifetime-mortality number.
Where the headline doesn’t apply. The sharpest risk elevation is genetic: carriers of a pathogenic BRCA1 or BRCA2 variant run a lifetime breast-cancer risk near 70% versus the ~13% baseline, per ACS — roughly 5× absolute incidence. The subgroup is real but small, affecting perhaps one woman in 400-500 in the general population; most breast cancer is not in BRCA carriers. First-degree family history roughly doubles baseline risk; dense breast tissue adds about 50%. Men are not zero — roughly 0.5-1% of breast cancers occur in men per WHO, which works out to about 1 in 800 US men diagnosed in their lifetime, but the overall male lifetime mortality figure sits around 3 in 10,000, nearly 100× lower than for women. The honest one-line summary: a diagnosis number close to 1 in 8 for US women, a death number close to 1 in 43 for US women and 1 in 59 for women globally. If you were going to remember one thing from this page, it should be which of those two numbers the “1 in 8” actually is.
Related tidbits
Lung cancer kills more women annually than breast cancer, yet receives a fraction of the awareness funding and cultural attention. Pink ribbons outsell awareness of the actual leading cancer killer across genders.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] World Health Organization — Breast cancer — fact sheet
Breast cancer — fact sheet- Statistic
2.3 million women diagnosed with breast cancer and 670,000 deaths globally in 2022- Excerpt
“"In 2022, there were an estimated 2.3 million women diagnosed with breast cancer and 670 000 deaths globally. [...] Approximately 99% of breast cancers occur in women and 0.5-1% of breast cancers occur in men." ”
- Source data from
- 2024-03-13
- Accessed
- 2026-04-11 · archived copy
- Calculation
- WHO republishes IARC GLOBOCAN 2022 breast-cancer totals: ~2.3M new cases and ~670K deaths among women per year. Divided naively across ~3.5B adult women worldwide that is ~1.9 per 10,000 per year. Age-weighting (most breast cancer deaths occur between 50 and 74) puts the realistic cumulative lifetime mortality near 1.5-2% globally, consistent with — and slightly below — the ACS direct US estimate of ~2.3%.
- Independence
- WHO breast-cancer fact sheet republishes IARC GLOBOCAN headline numbers. Treat as partially dependent with any other IARC-derived source; used here as the authoritative top-line institutional citation.
-
[2] American Cancer Society — How Common Is Breast Cancer?
How Common Is Breast Cancer?- Statistic
Lifetime US female risk of developing breast cancer ~13% (1 in 8); lifetime risk of dying from breast cancer ~2.3% (1 in 43)- Excerpt
“"Overall, the average risk of a woman in the United States developing breast cancer sometime in her life is about 13%. This means there is a 1 in 8 chance she will develop breast cancer. [...] The chance that any woman will die from breast cancer is about 1 in 43 (about 2.3%)." ”
- Source data from
- 2025-01-16
- Accessed
- 2026-04-11 · archived copy
- Calculation
- ACS gives both figures explicitly. Lifetime incidence 13% (1 in 8) and lifetime mortality 2.3% (1 in 43) — a roughly 5.5× gap between diagnosis and death. This is the single most important calibration point on the page: most readers quote "1 in 8" as if it were a death rate, when it is in fact the *incidence* rate. The US 2.3% anchors the upper end of the global uncertainty band.
- Independence
- ACS derives its US lifetime-probability figures from SEER incidence and mortality data (NCI). SEER is a population-based cancer registry pipeline methodologically independent of IARC GLOBOCAN, which compiles national registry data globally.
-
[3] National Cancer Institute / SEER Program — Cancer Stat Facts: Female Breast Cancer
Cancer Stat Facts: Female Breast Cancer- Statistic
5-year relative survival 91.7%; localized-stage 5-year survival 100.0%; ~13.0% lifetime risk of diagnosis- Excerpt
“"Approximately 13.0 percent of women will be diagnosed with female breast cancer at some point during their lifetime, based on 2018-2021 data. [...] The 5-year relative survival for females with breast cancer is 91.7%, based on SEER 21 data from 2015-2021." ”
- Source data from
- 2025-04-17
- Accessed
- 2026-04-11 · archived copy
- Calculation
- SEER is the primary US surveillance dataset feeding the ACS lifetime-probability figures above. The 91.7% 5-year relative survival — and the 100% figure for localized-stage disease, which is ~64% of new diagnoses — is the mechanism that makes the diagnosis/death gap so large. Most breast cancer diagnosed in wealthy countries is not a death sentence.
- Independence
- SEER is the upstream data source that ACS cites; treat these two as partially dependent. SEER is included as the authoritative primary-pipeline citation.
-
[4] American Cancer Society — Breast Cancer Risk Factors You Cannot Change
Breast Cancer Risk Factors You Cannot Change- Statistic
BRCA1/BRCA2 pathogenic variant carriers: ~70% lifetime breast cancer risk by age 80- Excerpt
“"On average, a woman with a BRCA1 or BRCA2 gene mutation has up to a 7 in 10 chance of getting breast cancer by age 80." ”
- Source data from
- 2024-12-19
- Accessed
- 2026-04-11 · archived copy
- Calculation
- ~70% lifetime breast cancer risk for BRCA1/BRCA2 carriers vs ~13% baseline for US women = roughly 5× absolute incidence elevation. BRCA pathogenic variants affect roughly 1 in 400-500 women in the general population, so the subgroup is real but small; the great majority of breast cancer occurs in non-carriers. Used to calibrate the personal_factor_multipliers block below.
- Independence
- ACS BRCA guidance synthesises results from the BRCA1/2 cohort literature (BCLC, kConFab, CARRIERS, etc.). Addresses genetic subgroup risk rather than the population-level mortality headline, so is methodologically distinct from the WHO/IARC and SEER pipelines above; used only to calibrate the personal-factor multipliers.